Among them is the BiKE AFM13 (Affimed), binding CD16A on NK cells and CD30 on tumor cells, which is currently being evaluated in a phase 1/2 trial in patients with CD30-positive relapsed or refractory Hodgkin and non-Hodgkin lymphomas. Here, FCGR3A is linked to neoplasm.